Surgical cytoreduction for recurrent epithelial ovarian cancer - Wikidata - wikimedia - TriplyDB

Surgical cytoreduction for recurrent epithelial ovarian cancer

Surgical cytoreduction for recurrent epithelial ovarian cancer

http://www.wikidata.org/entity/Q24200882

about

Repeat cytoreductive surgery with hyperthermic intraperitoneal chemotherapy: review of indications and outcomes OvMark: a user-friendly system for the identification of prognostic biomarkers in publically available ovarian cancer gene expression datasets.Dual-color labeled anti-mucin 1 antibody for imaging of ovarian cancer: A preliminary animal study Phthalocyanine-loaded graphene nanoplatform for imaging-guided combinatorial phototherapy.Estimating health-state utility values for patients with recurrent ovarian cancer using Functional Assessment of Cancer Therapy - General mapping algorithms The Lymphocyte-Monocyte Ratio Predicts Patient Survival and Aggressiveness of Ovarian Cancer Assessment of survival of patients with metastatic clear cell renal cell carcinoma after radical cytoreductive nephrectomy versus no surgery: a seer analysis.The role of secondary cytoreduction in low-grade serous ovarian cancer or peritoneal cancer.Feasibility of laparoscopic cytoreduction in patients with localized recurrent epithelial ovarian cancer.Targeting AMPK signaling in combating ovarian cancers: opportunities and challenges.Effects of poly (ADP-ribosyl) polymerase (PARP) inhibitor on cisplatin resistance & proliferation of the ovarian cancer C13* cells Comparison of survival outcomes after recurrence detected by cancer antigen 125 elevation versus imaging study in epithelial ovarian cancer.Current approaches and challenges in managing and monitoring treatment response in ovarian cancer.Secondary Surgery Versus Chemotherapy for Recurrent Ovarian Cancer.Hyperthermic Intraperitoneal Chemotherapy after Secondary Cytoreduction in Epithelial Ovarian Cancer: A Single-center Comparative Analysis.A Predictive Score for Secondary Cytoreductive Surgery in Recurrent Ovarian Cancer (SeC-Score): A Single-Centre, Controlled Study for Preoperative Patient Selection.Laparoscopic-based score assessment combined with a multiple disciplinary team in management of recurrent ovarian cancer: A single-center prospective study for personalized surgical therapy.Inhibitory effect of black tea pigments, theaflavin‑3/3'-gallate against cisplatin-resistant ovarian cancer cells by inducing apoptosis and G1 cell cycle arrest.Bitter Melon (Momordica charantia) Extract Inhibits Tumorigenicity and Overcomes Cisplatin-Resistance in Ovarian Cancer Cells Through Targeting AMPK Signaling Cascade.Theaflavin-3,3'-Digallate Enhances the Inhibitory Effect of Cisplatin by Regulating the Copper Transporter 1 and Glutathione in Human Ovarian Cancer Cells.Wounding promotes ovarian cancer progression and decreases efficacy of cisplatin in a syngeneic mouse model.Synergistic effect of black tea polyphenol, theaflavin-3,3'-digallate with cisplatin against cisplatin resistant human ovarian cancer cells

P2860

Q26768299-8CBB776D-F069-4AB5-A4B7-0F271E39D4DE Q34447404-93060A9E-151C-4A8F-A3BA-7AC3B7B0E96D Q35042084-41F3F500-C974-4BE9-865A-20A1901BCC64 Q35229094-2F5699F9-6DF0-4621-A7C7-4EFA8043C833 Q36332234-0F6482CD-AFF9-4086-A394-F428497265C1 Q36563905-8BF9E5C2-C831-431B-8315-30869BEBA49F Q36575806-A93F99B4-8BE6-4444-9A56-D6D06A9775E4 Q36751103-EE677CAF-3F97-449B-A43C-9AA268811AF7 Q36772920-0D853FB9-8382-4940-8C9B-8D4773A64163 Q36949580-A9A2FE33-0D3E-423B-8168-9359BE35EE25 Q36994946-24E47DA9-7D35-4D3A-BD96-3A5D846A1A33 Q37092776-A985CA73-E813-4569-AFB6-07CD45F60D3F Q37435187-5DD7BF7C-CB09-49B5-BB5F-F22FAE9499DF Q39621533-8683AFAA-F85F-4221-A761-25602F9B3D63 Q40251231-1231B3E9-5888-442F-978D-0715AF7D38B6 Q41161911-7A449787-9A58-423D-AB9B-BDDA981C8526 Q42170049-0E938323-58AD-40A4-B0A2-B31501B81E87 Q42378299-BA821B7B-0407-48D4-8F46-5A0D62C02714 Q46799064-BF1FFCCE-39BB-4DC0-8AF0-9F9CF958F479 Q47232215-DC87B045-44EF-4850-883F-798A6F0BCE04 Q55663308-DF99CF20-771F-49C3-86F2-53AAC52EDA8C Q58570585-3513971E-252C-4557-9844-4630D421F830

P2860

Surgical cytoreduction for recurrent epithelial ovarian cancer

http://www.wikidata.org/entity/Q24200882

description

2013 nî lūn-bûn

@nan

2013 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

Surgical cytoreduction for recurrent epithelial ovarian cancer

@ast

Surgical cytoreduction for recurrent epithelial ovarian cancer

@en

Surgical cytoreduction for recurrent epithelial ovarian cancer

@en-gb

Surgical cytoreduction for recurrent epithelial ovarian cancer

@nl

type

label

Surgical cytoreduction for recurrent epithelial ovarian cancer

@ast

Surgical cytoreduction for recurrent epithelial ovarian cancer

@en

Surgical cytoreduction for recurrent epithelial ovarian cancer

@en-gb

Surgical cytoreduction for recurrent epithelial ovarian cancer

@nl

prefLabel

Surgical cytoreduction for recurrent epithelial ovarian cancer

@ast

Surgical cytoreduction for recurrent epithelial ovarian cancer

@en

Surgical cytoreduction for recurrent epithelial ovarian cancer

@en-gb

Surgical cytoreduction for recurrent epithelial ovarian cancer

@nl

P1433

Q24200882-D7B656FB-BCC4-4CF2-B760-B6BC0D524DFC

P1476

Q24200882-DD660A3E-38D6-4C8C-94EA-E7B21C5BF742

P2093

Q24200882-07DBAC61-4C3C-407E-865C-FCDE29809D15

Q24200882-2901FC32-D5CD-41A7-ACBE-FFAFCAB4F0D5

Q24200882-57CEEF2B-2067-4323-83B4-08462E303428

Q24200882-67B7EA56-15CF-4985-9579-DD5B9D2F4061

Q24200882-701F11EC-F0EE-415C-941F-23F58EF47EDD

Q24200882-E12F2EFE-9921-4E56-8D35-AAC1E4EC4614

Q24200882-E64D99F4-329A-46B8-9FC7-A881E77526EA

P2860

Q24200882-00CCE61E-7033-4524-80EE-1B4208E9C783

Q24200882-0330D97D-2298-4C4E-9994-BF01E35831B2

Q24200882-090DADD8-D1F1-42BC-B6FD-12E2D6EE4E3D

Q24200882-145B14C6-BD2A-4490-A937-66055236BC96

Q24200882-1D8EBB30-EAC2-4845-B555-2B37C611482B

Q24200882-26055FF3-C18C-4919-ACE4-F356DCBCA735

Q24200882-46D013B6-AE4A-4547-9595-215B287131CC

Q24200882-52A9FC07-CF3E-424D-8A29-AE0F609831E8

Q24200882-64BB037D-7299-4696-B99E-DBA6F5CDC3E5

Q24200882-667A4B4D-D038-4692-B73A-1E2B522E5373

P304

Q24200882-69CC1684-A97C-49FF-B770-19B9EADDE6F8

P31

Q24200882-08351a4d-704d-4a1d-840c-66487443e391

Q24200882-62258E69-5C77-4D53-BEE9-2088CFC95795

P3181

Q24200882-050BC639-ADFB-47E1-8A0B-59E413680CFE

P356

Q24200882-959980CB-E20C-41D3-91B2-43866D6EB235

P433

Q24200882-FCC04338-65E9-45AF-8DC6-039D8373940F

P577

Q24200882-8F4F0F63-011A-4E07-8165-BA3BD2969CD7

P5875

Q24200882-591EB719-DD14-4E94-8C81-B9D4787E4AFF

P698

Q24200882-8342687E-2099-49E1-9C95-95E94E12EB39

P921

Q24200882-7132A79E-8327-469E-8F04-A122EE1D1C02

P932

Q24200882-62B006AD-8AB2-416F-8141-E73F2B9F6F91

P3181

P356

14651858.CD008765.PUB3

P1433

Cochrane Database of Systematic Reviews

P1476

Surgical cytoreduction for recurrent epithelial ovarian cancer

@en

P2093

Ahmed Elattar

http://www.w3.org/2001/XMLSchema#string

Alberto D Lopes

http://www.w3.org/2001/XMLSchema#string

Andrew Bryant

http://www.w3.org/2001/XMLSchema#string

Khadra Galaal

http://www.w3.org/2001/XMLSchema#string

Robert E Bristow

http://www.w3.org/2001/XMLSchema#string

Supratik Chattopadhyay

http://www.w3.org/2001/XMLSchema#string

Thuria Al Rawahi

http://www.w3.org/2001/XMLSchema#string

P2860

Cytoreductive surgery plus chemotherapy versus chemotherapy alone for recurrent epithelial ovarian cancer

Optimal primary surgical treatment for advanced epithelial ovarian cancer

Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints

Measuring inconsistency in meta-analyses

Meta-analysis in clinical trials

Topotecan for the treatment of advanced epithelial ovarian cancer: an open-label phase II study in patients treated after prior chemotherapy that contained cisplatin or carboplatin and paclitaxel.

Secondary cytoreductive surgery for localized intra-abdominal recurrences in epithelial ovarian cancer.

Ovarian carcinoma diagnosis.

Critical evaluation of secondary cytoreduction in recurrent ovarian cancer.

Surgical cytoreduction in recurrent ovarian carcinoma in patients with complete response to paclitaxel-platinum.

P304

CD008765

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

1767407

http://www.w3.org/2001/XMLSchema#string

P356

10.1002/14651858.CD008765.PUB3

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P577

2013-02-28T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

235757349

http://www.w3.org/2001/XMLSchema#string

P698

23450588

http://www.w3.org/2001/XMLSchema#string

P921

P932

6457850

http://www.w3.org/2001/XMLSchema#string